Anadys Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Anadys Pharmaceuticals, Inc.
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.
Cancer deals involve City of Hope/Chimeric, CARISMA/NYU, Sorrento/Mayo Clinic, Rain/Drexel, Diaprost/Memorial Sloan Kettering, Alkido/University of Kentucky. Plus, research collaborations in brief.
Companies in talks with EU authorities for the supply of at least 200 million initial doses of their mRNA vaccine. Plus, other new partnerships around the world and an India pause for AstraZeneca's contender in line with global decision.
Filsuvez has the potential to become the first treatment approved for epidermolysis bullosa, a rare genetic condition where skin can tear and blister at even the slightest touch.